Lab21 press releases

• 31.08.10 /Lab21 launches new commercial companion diagnostic service for HIV tropism in UK
• 26.08.10 /Lab21 licences pharmacogenetic IP for CES-1 from MUSC
• 01.06.10 /Lab21 achieves first product registration in China
• 24.05.10 /Lab21 and Virco partner to offer UK-based HIV-1 genotyping services
• 18.12.09 /Lab21 acquires US nanotechnology company and establishes Lab21 Inc. in South Carolina
• 26.11.09 /Lab21 acquires personalised medicine diagnostic services business
• 17.11.09 /Lab21 launches new high sensitivity immunodiagnostic system for CMV antibody detection
• 15.09.09 /Lab21 signs agreement with AstraZeneca to provide genetic testing service in lung cancer
• 04.08.09 /Lab21 Ltd to Provide AdnaGen’s CE-Marked System for the Detection and Analysis of Circulating Tumor Cells (CTCs) in the United Kingdom and Irelandt
• 21.07.09 / Lab21 announces publication of syphilis diagnostic patent
• 22.06.09 / Lab21 expands its predisposition oncology service portfolio with A NEW TEST TO DETERMINE SMOKERS’ LUNG CANCER RISK
• 16.06.09 / Lab21 partners with Innogenetics to build comprehensive HCV drug resistance IP portfolio
• 27.05.09 / Lab21 expands oncology portfolio with 5-FU personalised chemotherapy management service
• 24.03.09 / Lab21’s NP Tech division gains CPA accreditation
• 27.01.09 / Lab 21 and Breasthealth UK form partnership for breast health management
• 16.12.08 / Lab21 launches new 3 day service to identify Fungal Pneumonia
• 17.10.08 / Lab21 Expands International Business with Launch into India with a Million Dollar Syphilis Testing Agreement
• 17.10.08 / Lab21 spins out environmental monitoring business to Cogent Environmental Ltd
• 9.10.08 / Lab21 to market deCODE BreastCancer™, a Genetic Test to Screen for Risk of the Most Common Forms of Breast Cancer
• 24.09.08 / Lab21 expands its range of cardiovascular genetic tests with Clinical Data, Inc.
• 12.08.08 / Lab21 to market deCODE tests for assessing risk of common diseases
• 16.07.08 / Lab21 expands companion diagnostic cancer testing service internationally
• 25.06.08 / Lab21 expands cancer gene testing service
• 17.03.08 / Predictive genetic test for bowel cancer treatment is introduced in the UK
• 21.02.08 / Lab21 signs a license with Celera for one of the first diagnostic tests for cirrhosis risk in hepatitis C patients
• 23.01.08 / Lab21 launches cancer gene testing service
• 05.10.07 / Ark outlicenses marketing rights for Ox-LDL heart attack risk test kit to Lab21